VisCardia, a privately held medical device developer in Portland, Oregon, has concluded preclinical and First-in-Human trials to demonstrate safety of the implant procedure and its proprietary Synchronized Diaphragmatic StimulationTM therapy.
Leadership
Peter Bauer, Ph.D.
President & CEO
Peter is the President and CEO of VisCardia. He most recently served as President of Inovise Medical, after leading as its EVP of R&D. He previously held various leadership positions at BIOTRONIK focused on research and technology in their cardiac rhythm management division.
Gregg Harris, M.B.A.
VP Clinical & Regulatory
Gregg leads clinical and regulatory for VisCardia. He has worked in the fields of invasive & non-invasive cardiology, cardiac surgery, cardiac electrophysiology and heart failure for over 35 years in a variety of clinical, regulatory and commercial functions. He is a member of the Regulatory Affairs Professionals Society and is certified by IBHRE in both Cardiac Devices and Electrophysiology.
Michael Mirro, M.D.
Medical Affairs
Mike has pioneered implantable medical device development as a renowned physician investigator for over 35 years. He is board certified in internal medicine, cardiovascular disease, cardiac electrophysiology, and geriatrics, and has served as a principal investigator for over 100 clinical trials, and as a clinical advisor for multiple medical technology companies.
Clinical Advisors
Michael J Mirro, M.D.
Senior Vice President and Chief Academic Research Officer at Parkview Health, Director of the Mirro Center for Research and Innovation at Parkview, and Clinical Professor of Medicine at Indiana University.John Cleland, M.D.
Professor of Cardiology at Imperial College London and Director of the Robertson Centre for Biostatistics in Glasgow. Former chairman of the British Society for Heart Failure and of the Working Group on Heart Failure of the ESC, and founder of the European Journal of Heart Failure.Lee R. Goldberg, M.D., MPH
Professor of Medicine and Section Chief of Advanced Heart Failure and Cardiac Transplant at the University of Pennsylvania and Vice Chair of Medicine for Informatics. Published >90 articles/chapters and lectured worldwide on heart failure, cardiac transplant, mechanical circulatory support, medical informatics/data analytics, sleep apnea and palliative care.Michel Zuber, M.D.
Professor of Cardiology and Internal Medicine at the University Hospital of Zurich, Switzerland, specializing in diagnostic, advanced and interventional echocardiography, with a clinic for non-invasive cardiology and implantable arrhythmia and heart failure devices.Marat Fudim, MD, MHS
Assistant Professor of Medicine and co-director of the Heart Failure Research Unit at Duke University. Dr. Fudim is also a member of the research committee for the Heart Failure Society of America.Board of Directors
Peter Bauer, Ph.D.
Board Member
Peter is the President and CEO of VisCardia. He most recently served as President of Inovise Medical, after leading as its EVP of R&D. He previously held various leadership positions at BIOTRONIK focused on research and technology in their cardiac rhythm management division.
David Chazanovitz
Chairman of the Board
Dave is the Chairman of the Board for VisCardia, most recently serving as the Chairman of the Board of Inovise Medical, and President and CEO of Alveolus. He previously served as President and CEO of Cambridge Heart, and President of several divisions of C.R. Bard.
Dallas Ross
Board Member
Dallas Ross is a GP and founder of Kinetic Capital Partners in Vancouver BC which holds control positions in several private US high growth medical and software companies. He is active on the Board of each of Kinetic’s private companies and several other substantial public companies with operations in the US and Canada. Prior to Kinetic, Mr. Ross was an investment banker in Toronto and Vancouver.